Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Free Cash Flow (2021 - 2025)

Krystal Biotech's Free Cash Flow history spans 5 years, with the latest figure at $84.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 61.89% year-over-year to $84.3 million; the TTM value through Dec 2025 reached $197.8 million, up 65.96%, while the annual FY2025 figure was $197.8 million, 65.96% up from the prior year.
  • Free Cash Flow for Q4 2025 was $84.3 million at Krystal Biotech, up from $31.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $84.3 million in Q4 2025 and bottomed at -$59.6 million in Q2 2022.
  • The 5-year median for Free Cash Flow is -$10.1 million (2021), against an average of $1.9 million.
  • The largest annual shift saw Free Cash Flow crashed 326.26% in 2022 before it surged 2936.58% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$13.0 million in 2021, then surged by 180.51% to $10.5 million in 2022, then tumbled by 175.46% to -$7.9 million in 2023, then surged by 756.43% to $52.0 million in 2024, then skyrocketed by 61.89% to $84.3 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Free Cash Flow are $84.3 million (Q4 2025), $31.2 million (Q3 2025), and $57.6 million (Q2 2025).